Bank of New York Mellon Corp lowered its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,021,956 shares of the biopharmaceutical company’s stock after selling 29,688 shares during the period. Bank of New York Mellon Corp owned about 1.36% of Alexion Pharmaceuticals worth $375,176,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Bain Capital Public Equity Management LLC lifted its holdings in shares of Alexion Pharmaceuticals by 23.2% during the second quarter. Bain Capital Public Equity Management LLC now owns 70,753 shares of the biopharmaceutical company’s stock worth $8,784,000 after purchasing an additional 13,318 shares during the period. Brown Advisory Inc. raised its position in Alexion Pharmaceuticals by 297.9% during the second quarter. Brown Advisory Inc. now owns 20,261 shares of the biopharmaceutical company’s stock valued at $2,516,000 after acquiring an additional 15,169 shares in the last quarter. Essex Financial Services Inc. purchased a new position in Alexion Pharmaceuticals during the second quarter valued at approximately $232,000. Tyers Asset Management LLC raised its position in Alexion Pharmaceuticals by 15.5% during the second quarter. Tyers Asset Management LLC now owns 6,050 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 814 shares in the last quarter. Finally, CIBC Asset Management Inc raised its position in Alexion Pharmaceuticals by 2.0% during the second quarter. CIBC Asset Management Inc now owns 55,003 shares of the biopharmaceutical company’s stock valued at $6,829,000 after acquiring an additional 1,091 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Several brokerages recently weighed in on ALXN. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Barclays lifted their price target on Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research report on Friday, September 28th. Evercore ISI reiterated an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research report on Thursday, July 26th. JPMorgan Chase & Co. boosted their price objective on Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $123.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, July 27th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $161.50.
NASDAQ ALXN traded up $1.29 on Thursday, reaching $118.11. 812,584 shares of the company were exchanged, compared to its average volume of 1,811,813. The firm has a market capitalization of $26.06 billion, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 1.01 and a beta of 0.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the company posted $1.44 earnings per share. The firm’s revenue for the quarter was up 19.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theenterpriseleader.com/2018/11/22/alexion-pharmaceuticals-inc-alxn-holdings-lowered-by-bank-of-new-york-mellon-corp.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.